SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy’s Laboratories informs about updates

05 Mar 2026 Evaluate

In reference to intimation dated December 12, 2025, wherein the company had informed regarding a GMP and a Pre-Approval Inspection (PAI) conducted by the United States Food & Drug Administration (USFDA) at its formulations manufacturing facility (FTO-SEZ PU01) in Srikakulam, Andhra Pradesh, Dr. Reddy’s Laboratories has informed that the Company has received the Establishment Inspection Report (EIR) on March 04, 2026. The USFDA has classified the inspection outcome as 'Voluntary Action Indicated (VAI)' and concluded that the inspection is officially closed under 21 CFR 20.64(d)(3).

The above information is a part of company’s filings submitted to BSE.

Dr. Reddys Labs. Share Price

1240.90 -28.90 (-2.28%)
10-Jul-2026 14:44 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1930.00
Dr. Reddys Labs. 1240.90
Cipla 1437.80
Zydus Lifesciences 1148.40
Lupin 2495.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: